Skip to content

Comparing Tissue Adhesives in Port Site Closure

Comparing Tissue Adhesives in Port Site Closure: A Randomized Controlled Trial

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05492721
Enrollment
180
Registered
2022-08-08
Start date
2022-06-29
Completion date
2025-06-23
Last updated
2026-02-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dermatitis, Contact

Keywords

GLUE, SURGICAL GLUE, DERMABOND, DERMATITIS

Brief summary

This is a multi-center randomized controlled trial to evaluate two different methods of reinforcing surgical port site closure: 2-Octylcyanoacrylate and n-butyl-2-cyanoacrylate.

Detailed description

Study Design This is a multi-center randomized controlled trial to evaluate two different methods of reinforcing surgical port site closure: 2-Octylcyanoacrylate and n-butyl-2-cyanoacrylate. Methods Inclusion Criteria All adult patients undergoing an elective laparoscopic or robotic abdominal surgery with the Minimally Invasive Surgeons of Texas (MIST) either at Texas Medical Center or Sugar Land will be eligible. Exclusion criteria 1. Patients unlikely to follow-up (live out of state, unable to be reached by phone or email) 2. Patients with a known allergy to 2-Octylcyanoacrylate or N-butyl-2-cyanoacrylate. Treatment Groups Eligible patients will be approached by research staff either in clinic or in pre-operative holding for trial enrollment. Each patient will serve as their own control. Enrolled patients will have both surgical glue types used, one on each half of their abdomen. The side for each glue will be randomly assigned by the day of the month. On odd days, 2-Octylcyanoacrylate will go on the patient's left abdomen. On even days, 2-Octylcyanoacrylate will go on the patient's right abdomen. If there is an odd number of incisions, the extra incision will be included on the patient's left. All incisions will be closed with Monocryl. Closed incisions will be covered with skin glue. Outcome The primary outcome of this trial will be the proportion of patients with contact dermatitis within 6 weeks post-operative. A trained surgical clinician blinded to the treatment arms will collect outcomes at all follow up clinic visits in the first 6 weeks post-operative. Any skin reaction will be documented with photographs. Secondary outcome will include the diameter of erythema around any skin reaction, or any wound dehiscence or surgical site infection.

Interventions

Incisions on left will have one glue and on right will have the other glue

Incisions on left will have one glue and on right will have the other glue

Sponsors

The University of Texas Health Science Center, Houston
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Masking description

Outcome assessor does not know which glue was used

Intervention model description

Each subject will have both glue types and serve as their own control

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* 18 or older * undergoing an elective laparoscopic or robotic abdominal surgery

Exclusion criteria

* Patients unlikely to follow-up (live out of state, unable to be reached by phone or email) * Patients with a known allergy to 2-Octylcyanoacrylate or N-butyl-2-cyanoacrylate.

Design outcomes

Primary

MeasureTime frameDescription
proportion of patients who develop contact dermatitis6 weekserythema or rash around incisions

Secondary

MeasureTime frameDescription
mean diameter of erythema6 weeksmean diameter of erythema around incisions for those with contact dermatitis
proportion of patients with wound dehiscence6 weeksopening of incisions
proportion of patients with surgical site infection6 weeksCDC definition of surgical site infection

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 10, 2026